Flamel notified of FDA to unapproved manufacturers of neostigmine methylsulfate Flamel Technologies has received communication from the FDA that all manufacturers of unapproved versions of neostigmine methylsulfate have been notified by the FDA to cease manufacturing of the unapproved product as of July 30. Current inventory in the channel of the unapproved product can continue to be sold. Flamel has not been provided with information on the inventory levels held by these manufacturers.
Perrigo and Flamel enter into exclusive licensing agreement for LiquiTime Perrigo (PRGO) and Flamel (FLML) announced that they have entered into an exclusive licensing agreement for LiquiTime(R) extended release suspension. The technology will be utilized in the development of a portfolio of extended release suspension products intended for the U.S. OTC marketplace.